


Unrivaled Long-term data

For your patients who need
drug-eluting technology,
choose the only SFA DES
proven¹ through 5 years.



Zilver[®] PTX[®]




DRUG-ELUTING PERIPHERAL STENT

COOK[®]
MEDICAL

1. Dake MD, Ansel GM, Jaff MR, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. *Circulation*. 2016;133(15):1472-83.


Simplified*, precise** deployment

- One-handed thumbwheel provides simplified, precise stent deployment
- Paclitaxel is coated onto the Zilver Flex® stent platform
- Available in lengths up to 140 mm
- Diameters as small as 5 mm





*Simplified compared to previous Zilver PTX pin-and-pull delivery system

** PTX Thumbwheel Delivery System. D00061841 (2017).



Proven data

5-year RESULTS




NOTE: Results are from the secondary randomization of Zilver PTX vs. Zilver bare-metal stent.

1. Dake MD, Ansel GM, Jaff MR, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. *Circulation*. 2016;133(15):1472-83.

*The 1-year primary endpoints of EFS and primary patency showed superiority of primary DES compared to PTA, and these results were sustained through 5 years. Primary Patency is 64.0% (DES) vs. 19.0% (PTA), $p < 0.01$. The EFS rate through 5 years for the primary DES group was significantly greater than that for PTA (Kaplan-Meier estimates 81.4% versus 70.1%, $p < 0.01$, log-rank). The most common end to EFS through 5 years was TLR, which occurred at rates of 16.1% for primary DES and 28.0% for PTA ($p < 0.01$). In the per-protocol analyses of EFS and TLR, the PTA group included patients with optimal PTA, patients receiving provisional BMS, and patients receiving provisional DES.

3 essentials for achieving 5-year results



1. Dake MD, Ansel GM, Jaff MR, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. *Circulation*. 2016;133(15):1472-83.

2. Axel D, Kunert W, Göggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. *Circulation*. 1997; Jul 15;96(2):636-45.

3. Dake MD, Van Alstine WG, Zhou Q, et al. Polymer-free paclitaxel-coated Zilver PTX Stents—evaluation of pharmacokinetics and comparative safety in porcine arteries. *J Vasc Interv Radiol*. 2011;22(5):603-610.

4. Litsky J, Chanda A, Stilp E, et al. Critical evaluation of stents in the peripheral arterial disease of the superficial femoral artery - focus on the paclitaxel eluting stent. *Med Devices (Auckl)*. 2014;7:149-156.


5. Torii S, Yahagi K, Mori H, et al. Biologic drug effect and particulate embolization of drug-eluting stents versus drug-coated balloons in healthy swine femoropopliteal arteries. *J Vasc Interv Radiol*. 2018; 29(7):1041-1049.

Time-tested Technology¹

Zilver PTX is the first drug-eluting stent approved for the SFA.

Paclitaxel inhibits neointimal hyperplasia¹ and has been proven over 5 years to reduce restenosis and reinterventions compared to bare-metal Zilver stents.¹


HOW DRUG ELUTION WORKS



Release:


> 98% of the paclitaxel coating is released from the stent within 72 hours.*²

Cook Medical's proprietary, polymer-free coating process eliminates the potential risks associated with polymers.



Absorption:

Paclitaxel remains in the artery for **up to 56 days.*²**



Inhibiting:

Inside the cell, the drug binds to microtubules and inhibits mitosis.²

*Based on pharmacokinetic studies in porcine models.

1. Dake MD, Ansel GM, Jaff MR, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. *Circulation*. 2016;133(15):1472-83.

2. Dake MD, Van Alstine WG, Zhou Q, et al. Polymer-free paclitaxel-coated Zilver PTX Stents—evaluation of pharmacokinetics and comparative safety in porcine arteries. *J Vasc Interv Radiol*. 2011;22(5):603-610.


Ordering Information

Order Number	Reference Part Number	Accepts Wire Guide Diameter inch	Stent Diameter mm	Stent Length mm	Minimum Sheath Fr
125 cm Over-the-Wire Delivery System					
G38404	ZISV6-35-125-5-40-PTX	0.035	5	40	6
G38407	ZISV6-35-125-5-60-PTX	0.035	5	60	6
G38408	ZISV6-35-125-5-80-PTX	0.035	5	80	6
G38414	ZISV6-35-125-5-100-PTX	0.035	5	100	6
G38415	ZISV6-35-125-5-120-PTX	0.035	5	120	6
G38416	ZISV6-35-125-5-140-PTX	0.035	5	140	6
G38463	ZISV6-35-125-6-40-PTX	0.035	6	40	6
G38479	ZISV6-35-125-6-60-PTX	0.035	6	60	6
G38480	ZISV6-35-125-6-80-PTX	0.035	6	80	6
G38481	ZISV6-35-125-6-100-PTX	0.035	6	100	6
G38482	ZISV6-35-125-6-120-PTX	0.035	6	120	6
G38483	ZISV6-35-125-6-140-PTX	0.035	6	140	6
G38486	ZISV6-35-125-7-40-PTX	0.035	7	40	6
G38487	ZISV6-35-125-7-60-PTX	0.035	7	60	6
G38488	ZISV6-35-125-7-80-PTX	0.035	7	80	6
G38489	ZISV6-35-125-7-100-PTX	0.035	7	100	6
G38490	ZISV6-35-125-7-120-PTX	0.035	7	120	6
G38491	ZISV6-35-125-7-140-PTX	0.035	7	140	6
G38495	ZISV6-35-125-8-40-PTX	0.035	8	40	6
G38516	ZISV6-35-125-8-60-PTX	0.035	8	60	6
G38518	ZISV6-35-125-8-80-PTX	0.035	8	80	6
G38523	ZISV6-35-125-8-100-PTX	0.035	8	100	6
G38532	ZISV6-35-125-8-120-PTX	0.035	8	120	6


Some products or part numbers may not be available in all markets. Contact your local Cook representative or Customer Service for details.

Reference Part Number Key

ZISV6-35-125-5-40-PTX



Caution: Use of this drug-eluting peripheral stent carries the risks associated with peripheral artery stenting, including vascular complications and/or bleeding events. Refer to the Instructions for Use (IFU) for full prescribing information including information on potential adverse events, contraindications, warnings, and precautions.



Customer Service

EU Website: cookmedical.eu
EDI: cookmedical.eu/edi
Distributors: +353 61239240, ssc.distributors@cookmedical.com
Austria: +43 179567121, oe.orders@cookmedical.com
Belgium: +32 27001702, be.orders@cookmedical.com
Denmark: +45 38487607, da.orders@cookmedical.com
Finland: +358 972519996, fi.orders@cookmedical.com
France: +33 171230269, fr.orders@cookmedical.com
Germany: +49 6950072804, de.orders@cookmedical.com
Hungary: +36 17779199, hu.orders@cookmedical.com
Iceland: +354 800 7615, is.orders@cookmedical.com
Ireland: +353 61239252, ie.orders@cookmedical.com
Italy: +39 0269682853, it.orders@cookmedical.com
Netherlands: +31 202013367, nl.orders@cookmedical.com
Norway: +47 23162968, no.orders@cookmedical.com
Spain: +34 912702691, es.orders@cookmedical.com
Sweden: +46 858769468, se.orders@cookmedical.com
Switzerland - French: +41 448009609, fr.orders@cookmedical.com
Switzerland - Italian: +41 448009609, it.orders@cookmedical.com
Switzerland - German: +41 448009609, de.orders@cookmedical.com
United Kingdom: +44 2073654183, uk.orders@cookmedical.com

USA Website: cookmedical.com

EDI: cookmedical.com/edi.do

Americas:

Phone: +1 812.339.2235, 800.457.4500, Fax: 800.554.8335

E-mail: orders@cookmedical.com

Australia:

Phone: +61 734346000, 1800777222, Fax: +61 734346001, 1800077283

E-mail: cau.custserv@cookmedical.com



AI-ESC-IR-OHNS-PI-RH-SUR-A4